Company · ALNY
Alnylam Pharmaceuticals
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
4 still marketed
Novel approvals
4
Approvals since 2021
4
Originals and new uses
Phase 3 trials
15
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Amvuttra new use Priority reviewOrphanMar 20, 2025
- Onpattro new use OrphanJan 13, 2023
- Oxlumo new use OrphanOct 6, 2022
- Amvuttra approved NovelOrphanJun 13, 2022
- Oxlumo approved NovelBreakthrough therapyPriority reviewOrphanNov 23, 2020
- Givlaari approved NovelBreakthrough therapyPriority reviewOrphanNov 20, 2019
- Onpattro approved NovelBreakthrough therapyPriority reviewOrphanAug 10, 2018
Drugs in development (6)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- NucresiranALN-TTRSC04Phase 32 trials
Alnylam Pharmaceuticals · Transthyretin Amyloidosis With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
- ALN-4324Phase 22 trials
Alnylam Pharmaceuticals · Type 2 Diabetes Mellitus (T2DM), Obese or Overweight Healthy Volunteers
- ALN-6400Phase 22 trials
Alnylam Pharmaceuticals · Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB), Hereditary Hemorrhagic Telangiectasia
- mivelsiranALN-APPPhase 22 trials
Alnylam Pharmaceuticals · Cerebral Amyloid Angiopathy, Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- ALN-2232Phase 21 trial
Alnylam Pharmaceuticals · Obesity
Recruiting Phase 3 trials
Largest first.
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07052903 · 2,250 participants (planned) · Start Jul 2, 2025 · Primary completion May 28, 2030
Drug: Nucresiran; Sterile Normal Saline (0.9% NaCl) · For: Transthyretin Amyloidosis With Cardiomyopathy
Sites: La Jolla, California; Laguna Hills, California; Stanford, California · 267 sites in all
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07223203 · 125 participants (planned) · Start Feb 3, 2026 · Primary completion Dec 27, 2027
Drug: Nucresiran; Vutrisiran · For: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
Sites: Aurora, Colorado; Chicago, Illinois; Baltimore, Maryland · 61 sites in all
Marketed drugs (4)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.